DocMeetings

Our latest research, published in Nature Communications, describes the potential of routine cervical samples for detection and risk prediction of breast and ovarian cancers via assessment of new epigenetic women’s cancer risk identification (WID) signatures. In independent validation sets, breast and ovarian cancers were identified in independent validation sets with AUCs of 0.81 and 0.76, respectively.

In my talk, I will give an introduction and background into our research programme aiming to detect four women’s cancers – breast, ovarian, endometrial, and cervical – using a single test, present current results and introduce the methodology of this new test, and provide an insight into ongoing and future trials looking at longitudinal risk monitoring using the WID test.